D. E. Shaw & Co., Inc. Editas Medicine, Inc. Put Options Transaction History

D. E. Shaw & Co., Inc.

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2022 Aug 15, 2022	SELL	$9.99 - $21.35 $1.84 Million - $3.94 Million	-184,600 Reduced 82.19%	40,000 $473,000
Q1 2022 May 16, 2022	BUY	$14.08 - $27.63 $1.48 Million - $2.91 Million	105,400 Added 88.42%	224,600 $4.27 Million
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $1.04 Million - $1.59 Million	39,200 Added 49.0%	119,200 $3.17 Million
Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $2.75 Million - $5.11 Million	-70,000 Reduced 46.67%	80,000 $3.29 Million
Q2 2021 Aug 16, 2021	BUY	$31.29 - $56.64 $2.82 Million - $5.1 Million	90,000 Added 150.0%	150,000 $8.5 Million
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $2.38 Million - $5.43 Million	60,000 New	60,000 $2.52 Million

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.